

Supplementary Table 1: Variable definitions

Use	Name	Description
Stratification variable in all Cox models	JCVI group	Vaccine priority group defined by the UK Joint Committee on Vaccination and Immunisation (JCVI)
	Eligibility date	Date of eligibility for primary vaccine course
	Region	Region of England
Demographic covariate in adjusted Cox model	Age	Age on 31 March 2021
	Sex	Male, Female
	IMD	English Index of Multiple Deprivation (IMD) quintile
	Ethnicity	Census categories: White, Black, South Asian, Mixed, Other
Clinical covariate in adjusted Cox model	BMI	Body Mass Index (BMI): Not Obese, Obese I ($30\text{-}34.9 \text{ kg/m}^2$), Obese II ($35\text{-}39.9 \text{ kg/m}^2$), Obese III ($\geq 40 \text{ kg/m}^2$),
	Learning disability	Yes, no.
	Serious mental illness	Yes, no.
	Morbidity count	Number of morbidities in the following categories: chronic respiratory disease, chronic heart disease, chronic liver disease, chronic kidney disease, chronic neurological disease, diabetes, immunosuppression.
	Flu vaccine in previous 5 years	Yes, no
	Number of previous SARS-CoV-2 tests	Number of tests taken between 2022-05-18 and “Eligibility date”: 0, 1, 2, ≥ 3
	Pregnancy	Yes, no

Supplementary Table 2: Counts and hazard ratios (HR) for COVID-19 hospitalisation the 65+ years subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	73,248	70	845,964	28	0.08 (0.05,0.13)	0.08 (0.05,0.14)	1,117,900	42	0.12 (0.08,0.20)	0.14 (0.08,0.25)
7-10	66,794	112	844,536	35	0.07 (0.04,0.10)	0.06 (0.04,0.10)	1,116,185	91	0.09 (0.07,0.13)	0.09 (0.06,0.13)
11-14	64,050	196	842,940	126	0.10 (0.08,0.14)	0.10 (0.08,0.14)	1,114,295	343	0.16 (0.13,0.19)	0.15 (0.12,0.19)
15-18	61,355	322	840,945	308	0.13 (0.11,0.15)	0.12 (0.09,0.15)	1,111,915	602	0.17 (0.14,0.20)	0.16 (0.13,0.19)
19-22	60,123	329	838,754	413	0.16 (0.13,0.18)	0.15 (0.12,0.18)	1,109,290	763	0.23 (0.20,0.27)	0.22 (0.18,0.26)
23-26	58,310	315	835,975	581	0.23 (0.19,0.26)	0.21 (0.18,0.25)	1,105,643	861	0.30 (0.25,0.35)	0.26 (0.22,0.31)
27-30	57,673	364	798,217	686	0.23 (0.20,0.26)	0.20 (0.17,0.24)	1,040,172	1,008	0.29 (0.25,0.33)	0.26 (0.22,0.31)
31-34	56,007	427	168,616	301	0.40 (0.34,0.48)	0.36 (0.29,0.44)	185,465	399	0.54 (0.46,0.63)	0.45 (0.38,0.54)
35-38	54,859	511	40,061	189	0.75 (0.62,0.90)	0.60 (0.50,0.74)	48,293	252	0.93 (0.79,1.10)	0.70 (0.59,0.83)
39-42	52,885	441	19,012	126	1.06 (0.86,1.31)	0.87 (0.70,1.09)	27,671	126	1.14 (0.92,1.43)	0.92 (0.73,1.15)
43-46	52,101	343	14,490	84	1.31 (1.01,1.68)	0.97 (0.75,1.27)	24,087	91	1.43 (1.10,1.86)	1.07 (0.82,1.41)
47-50	50,736	259	12,425	63	1.35 (1.01,1.81)	0.98 (0.73,1.34)	18,277	70	1.45 (1.07,1.97)	1.12 (0.82,1.53)

Supplementary Table 3: Counts and hazard ratios (HR) for COVID-19 death the 65+ years subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	73,269	21	845,992	7	0.03 (0.01,0.08)	0.03 (0.01,0.08)	1,117,914	7		
7-10	66,829	21	844,585	7			1,116,241	7	0.05 (0.02,0.11)	0.07 (0.03,0.16)
11-14	64,106	42	843,017	14	0.05 (0.02,0.10)	0.05 (0.02,0.10)	1,114,435	35	0.10 (0.06,0.16)	0.09 (0.05,0.15)
15-18	61,474	77	841,127	42	0.08 (0.05,0.12)	0.06 (0.04,0.10)	1,112,356	84	0.10 (0.07,0.15)	0.08 (0.05,0.13)
19-22	60,319	105	839,195	98	0.11 (0.08,0.16)	0.10 (0.07,0.15)	1,110,249	133	0.12 (0.09,0.17)	0.11 (0.08,0.16)
23-26	58,653	98	836,731	112	0.13 (0.10,0.18)	0.13 (0.09,0.19)	1,107,232	133	0.17 (0.12,0.23)	0.15 (0.10,0.21)
27-30	58,072	91	799,386	133	0.19 (0.14,0.26)	0.16 (0.11,0.23)	1,042,377	175	0.25 (0.18,0.35)	0.21 (0.15,0.31)
31-34	56,525	105	169,659	77	0.39 (0.28,0.55)	0.28 (0.19,0.41)	187,117	119	0.66 (0.49,0.89)	0.44 (0.32,0.61)
35-38	55,496	126	40,782	56	0.79 (0.57,1.09)	0.56 (0.40,0.79)	49,266	56	0.84 (0.58,1.21)	0.59 (0.41,0.86)
39-42	53,676	119	19,481	35	0.96 (0.64,1.45)	0.70 (0.46,1.08)	28,378	35	1.38 (0.89,2.13)	0.97 (0.63,1.50)
43-46	53,060	98	14,868	21	0.98 (0.58,1.65)	0.68 (0.38,1.19)	24,717	14	1.23 (0.62,2.46)	0.96 (0.49,1.89)
47-50	51,772	56	12,782	14	0.90 (0.43,1.88)	0.67 (0.30,1.49)	18,816	7	0.94 (0.40,2.25)	0.77 (0.32,1.82)

Supplementary Table 4: Counts and hazard ratios (HR) for positive SARS-CoV-2 test the 65+ years subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	73,227	105	845,880	105	0.23 (0.16,0.31)	0.23 (0.16,0.33)	1,117,746	252	0.59 (0.45,0.79)	0.53 (0.39,0.71)
7-10	66,773	252	844,375	322	0.37 (0.30,0.45)	0.30 (0.24,0.38)	1,115,828	1,211	0.69 (0.59,0.81)	0.62 (0.52,0.74)
11-14	64,008	392	842,492	1,099	0.52 (0.46,0.60)	0.43 (0.37,0.50)	1,112,818	3,423	0.89 (0.79,1.00)	0.75 (0.66,0.86)
15-18	61,215	595	839,524	2,303	0.62 (0.56,0.69)	0.53 (0.47,0.60)	1,107,372	5,509	0.92 (0.84,1.02)	0.79 (0.71,0.87)
19-22	59,906	581	835,345	3,115	0.77 (0.69,0.85)	0.67 (0.59,0.75)	1,099,861	6,545	1.19 (1.08,1.31)	1.00 (0.90,1.12)
23-26	57,946	602	829,892	4,158	1.08 (0.98,1.19)	0.87 (0.78,0.97)	1,090,474	8,967	1.60 (1.46,1.76)	1.24 (1.12,1.36)
27-30	57,239	770	788,963	4,900	0.94 (0.86,1.02)	0.79 (0.71,0.87)	1,017,905	9,380	1.26 (1.16,1.37)	1.08 (0.98,1.18)
31-34	55,391	1,015	163,443	1,085	0.90 (0.81,1.00)	0.80 (0.71,0.90)	174,342	1,834	1.38 (1.26,1.52)	1.19 (1.07,1.31)
35-38	54,075	1,127	38,528	518	1.23 (1.10,1.39)	1.03 (0.91,1.17)	45,276	952	1.64 (1.48,1.80)	1.37 (1.24,1.53)
39-42	51,772	777	18,256	322	1.78 (1.54,2.05)	1.47 (1.26,1.72)	25,914	308	1.91 (1.64,2.23)	1.54 (1.31,1.81)
43-46	50,785	469	13,762	154	1.75 (1.43,2.14)	1.34 (1.08,1.65)	22,456	98	1.60 (1.24,2.07)	1.23 (0.95,1.59)
47-50	49,357	273	11,767	63	1.31 (0.98,1.75)	0.96 (0.71,1.30)	17,122	70	1.44 (1.06,1.96)	1.12 (0.82,1.54)

Supplementary Table 5: Counts and hazard ratios (HR) for non-COVID-19 death the 65+ years subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	73,269	385	845,992	854	0.31 (0.27,0.36)	0.28 (0.24,0.34)	1,117,914	812	0.43 (0.36,0.51)	0.34 (0.28,0.41)
7-10	66,829	301	844,585	1,092	0.44 (0.38,0.51)	0.40 (0.33,0.47)	1,116,241	973	0.60 (0.49,0.72)	0.50 (0.41,0.62)
11-14	64,106	280	843,017	1,274	0.54 (0.47,0.62)	0.51 (0.43,0.61)	1,114,435	1,148	0.62 (0.52,0.74)	0.60 (0.50,0.73)
15-18	61,474	259	841,127	1,337	0.57 (0.49,0.66)	0.51 (0.42,0.62)	1,112,356	1,253	0.77 (0.64,0.92)	0.65 (0.53,0.79)
19-22	60,319	259	839,195	1,393	0.61 (0.52,0.71)	0.60 (0.50,0.72)	1,110,249	1,190	0.65 (0.54,0.78)	0.65 (0.53,0.79)
23-26	58,653	273	836,731	1,568	0.58 (0.50,0.66)	0.52 (0.44,0.62)	1,107,232	1,372	0.72 (0.61,0.84)	0.68 (0.56,0.82)
27-30	58,072	280	799,386	1,582	0.65 (0.57,0.75)	0.61 (0.51,0.73)	1,042,377	1,400	0.76 (0.64,0.89)	0.70 (0.58,0.84)
31-34	56,525	266	169,659	1,057	1.64 (1.40,1.91)	1.25 (1.05,1.49)	187,117	791	1.94 (1.65,2.28)	1.41 (1.19,1.69)
35-38	55,496	287	40,782	567	3.33 (2.82,3.92)	2.40 (2.02,2.85)	49,266	455	3.40 (2.87,4.03)	2.41 (2.03,2.87)
39-42	53,676	287	19,481	266	3.40 (2.83,4.08)	2.72 (2.24,3.30)	28,378	203	3.14 (2.54,3.87)	2.53 (2.05,3.13)
43-46	53,060	252	14,868	126	2.63 (2.07,3.35)	2.11 (1.63,2.73)	24,717	154	3.31 (2.59,4.22)	2.67 (2.08,3.42)
47-50	51,772	175	12,782	91	2.53 (1.90,3.37)	2.00 (1.48,2.70)	18,816	70	2.36 (1.68,3.31)	1.87 (1.33,2.64)

Supplementary Table 6: Counts and hazard ratios (HR) for Any SARS-CoV-2 test the 65+ years subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	73,227	5,810	845,880	66,556	2.21 (2.15,2.28)	1.61 (1.56,1.67)	1,117,746	102,060	2.97 (2.88,3.06)	2.09 (2.02,2.16)
7-10	66,773	5,439	844,375	74,410	2.55 (2.48,2.63)	1.87 (1.80,1.93)	1,115,828	113,463	3.12 (3.02,3.22)	2.19 (2.12,2.27)
11-14	64,008	5,516	842,492	81,816	2.55 (2.48,2.63)	1.87 (1.80,1.93)	1,112,818	122,906	3.07 (2.98,3.17)	2.19 (2.12,2.27)
15-18	61,215	5,558	839,524	81,564	2.48 (2.40,2.56)	1.84 (1.78,1.91)	1,107,372	120,995	3.00 (2.91,3.10)	2.16 (2.09,2.23)
19-22	59,906	5,537	835,345	87,339	2.61 (2.53,2.69)	1.94 (1.87,2.00)	1,099,861	134,113	3.18 (3.09,3.28)	2.29 (2.22,2.37)
23-26	57,946	5,376	829,892	96,061	2.87 (2.79,2.96)	2.14 (2.07,2.21)	1,090,474	146,216	3.45 (3.35,3.56)	2.45 (2.38,2.53)
27-30	57,239	5,551	788,963	94,430	2.87 (2.78,2.95)	2.15 (2.08,2.22)	1,017,905	140,140	3.47 (3.36,3.57)	2.50 (2.42,2.58)
31-34	55,391	5,726	163,443	18,942	2.41 (2.32,2.49)	1.89 (1.82,1.97)	174,342	21,119	2.70 (2.61,2.80)	2.10 (2.02,2.18)
35-38	54,075	5,159	38,528	5,327	2.85 (2.73,2.98)	2.24 (2.13,2.35)	45,276	5,852	3.05 (2.92,3.19)	2.41 (2.30,2.53)
39-42	51,772	4,109	18,256	2,401	3.31 (3.13,3.51)	2.66 (2.50,2.83)	25,914	2,576	3.26 (3.07,3.46)	2.65 (2.49,2.82)
43-46	50,785	3,276	13,762	1,393	3.27 (3.05,3.51)	2.65 (2.46,2.85)	22,456	1,701	3.04 (2.83,3.26)	2.53 (2.35,2.72)
47-50	49,357	2,163	11,767	931	3.30 (3.03,3.60)	2.67 (2.43,2.92)	17,122	1,015	3.15 (2.87,3.46)	2.59 (2.36,2.85)

Supplementary Table 7: Counts and hazard ratios (HR) for COVID-19 hospitalisation the 18-64 years and clinically vulnerable subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	152,670	189	373,947	7	0.04 (0.02,0.10)	0.03 (0.01,0.08)	659,036	28	0.09 (0.06,0.14)	0.07 (0.04,0.11)
7-10	135,975	448	373,471	28	0.06 (0.04,0.08)	0.04 (0.03,0.06)	658,077	161	0.14 (0.12,0.17)	0.11 (0.09,0.14)
11-14	123,340	630	372,932	63	0.06 (0.05,0.08)	0.05 (0.04,0.06)	656,943	308	0.17 (0.14,0.19)	0.13 (0.11,0.15)
15-18	115,857	490	372,344	105	0.12 (0.10,0.15)	0.09 (0.07,0.11)	655,571	406	0.26 (0.23,0.30)	0.20 (0.17,0.24)
19-22	111,314	448	371,574	105	0.14 (0.11,0.17)	0.09 (0.07,0.11)	653,933	392	0.28 (0.24,0.33)	0.20 (0.17,0.23)
23-26	107,583	441	369,607	133	0.17 (0.14,0.21)	0.10 (0.08,0.13)	650,055	518	0.35 (0.30,0.40)	0.25 (0.21,0.29)
27-30	104,713	455	347,543	154	0.19 (0.16,0.23)	0.12 (0.10,0.15)	594,104	497	0.33 (0.29,0.38)	0.24 (0.21,0.29)
31-34	101,661	511	107,373	119	0.38 (0.31,0.47)	0.28 (0.22,0.35)	186,298	294	0.54 (0.46,0.63)	0.42 (0.36,0.50)
35-38	98,322	406	40,229	105	1.01 (0.80,1.26)	0.80 (0.64,1.01)	89,964	196	0.95 (0.79,1.15)	0.83 (0.69,1.01)
39-42	94,913	245	30,674	49	1.14 (0.80,1.62)	0.91 (0.64,1.30)	73,213	112	1.21 (0.95,1.54)	1.02 (0.80,1.31)
43-46	93,401	203	28,672	35	0.78 (0.53,1.15)	0.61 (0.41,0.90)	68,957	84	0.87 (0.66,1.14)	0.70 (0.53,0.92)
47-50	92,078	84	17,353	14	0.92 (0.50,1.71)	0.72 (0.38,1.38)	18,193	28	0.99 (0.62,1.60)	0.79 (0.48,1.30)

Supplementary Table 8: Counts and hazard ratios (HR) for COVID-19 death the 18-64 years and clinically vulnerable subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	152,677	14	373,961	0			659,050	7		
7-10	136,024	28	373,492	0			658,112	7	0.07 (0.02,0.23)	0.04 (0.01,0.13)
11-14	123,508	63	372,974	7			657,132	21	0.12 (0.07,0.20)	0.09 (0.05,0.16)
15-18	116,291	63	372,449	14	0.07 (0.03,0.14)	0.04 (0.02,0.08)	656,054	28	0.14 (0.09,0.23)	0.08 (0.05,0.13)
19-22	112,000	70	371,770	14	0.12 (0.07,0.23)	0.07 (0.04,0.14)	654,787	35	0.15 (0.10,0.24)	0.09 (0.06,0.15)
23-26	108,374	49	369,894	14	0.14 (0.07,0.28)	0.07 (0.03,0.14)	651,259	42	0.22 (0.14,0.34)	0.11 (0.07,0.17)
27-30	105,672	63	347,928	21	0.16 (0.09,0.28)	0.08 (0.04,0.15)	595,651	56	0.24 (0.16,0.36)	0.12 (0.08,0.19)
31-34	102,725	56	107,639	14	0.33 (0.16,0.65)	0.19 (0.10,0.37)	187,355	28	0.43 (0.26,0.69)	0.29 (0.17,0.50)
35-38	99,547	42	40,432	14	0.81 (0.38,1.73)	0.63 (0.30,1.36)	90,699	14	0.78 (0.41,1.48)	0.57 (0.30,1.10)
39-42	96,278	21	30,891	7			73,885	7	0.40 (0.14,1.18)	0.37 (0.13,1.07)
43-46	94,864	14	28,903	7			69,664	7	0.66 (0.18,2.45)	0.50 (0.11,2.25)
47-50	93,590	7	17,507	7			18,487	7		

Supplementary Table 9: Counts and hazard ratios (HR) for positive SARS-CoV-2 test the 18-64 years and clinically vulnerable subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	152,572	1,624	373,863	147	0.17 (0.14,0.21)	0.22 (0.18,0.27)	658,742	1,407	0.60 (0.55,0.65)	0.74 (0.67,0.80)
7-10	135,653	3,374	373,254	1,435	0.31 (0.29,0.34)	0.39 (0.36,0.42)	656,404	5,572	0.64 (0.61,0.67)	0.77 (0.73,0.81)
11-14	122,136	3,983	371,308	2,394	0.39 (0.36,0.41)	0.45 (0.42,0.48)	649,866	7,784	0.73 (0.70,0.76)	0.85 (0.81,0.89)
15-18	113,092	2,989	368,396	3,150	0.56 (0.53,0.59)	0.59 (0.55,0.63)	641,039	8,414	0.98 (0.93,1.02)	1.03 (0.98,1.09)
19-22	107,212	2,695	364,595	3,374	0.80 (0.75,0.85)	0.80 (0.75,0.86)	631,421	9,926	1.24 (1.19,1.30)	1.21 (1.15,1.27)
23-26	102,802	2,940	359,415	5,180	0.94 (0.89,0.99)	0.92 (0.86,0.97)	618,121	12,901	1.43 (1.37,1.50)	1.38 (1.31,1.44)
27-30	98,840	4,095	332,892	4,928	0.84 (0.80,0.89)	0.86 (0.81,0.91)	552,272	12,957	1.29 (1.24,1.35)	1.32 (1.26,1.38)
31-34	94,864	6,048	98,028	4,130	1.33 (1.27,1.39)	1.37 (1.31,1.44)	161,931	9,163	1.64 (1.58,1.70)	1.67 (1.61,1.73)
35-38	89,509	4,130	34,265	1,848	1.69 (1.60,1.79)	1.59 (1.50,1.70)	72,324	2,898	1.69 (1.60,1.78)	1.60 (1.51,1.70)
39-42	83,545	707	24,773	140	1.55 (1.27,1.90)	1.39 (1.13,1.71)	56,742	322	1.65 (1.42,1.92)	1.53 (1.31,1.79)
43-46	81,578	203	23,184	35	0.84 (0.57,1.25)	0.64 (0.43,0.97)	53,480	77	0.96 (0.73,1.27)	0.76 (0.57,1.01)
47-50	80,619	84	14,091	14	0.92 (0.49,1.75)	0.72 (0.37,1.41)	14,070	28	1.07 (0.67,1.71)	0.86 (0.52,1.42)

Supplementary Table 10: Counts and hazard ratios (HR) for non-COVID-19 death the 18-64 years and clinically vulnerable subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	152,677	147	373,961	133	0.69 (0.53,0.91)	0.45 (0.33,0.61)	659,050	196	0.51 (0.40,0.64)	0.34 (0.26,0.44)
7-10	136,024	154	373,492	133	0.56 (0.42,0.75)	0.35 (0.25,0.49)	658,112	245	0.52 (0.42,0.64)	0.33 (0.25,0.43)
11-14	123,508	133	372,974	147	0.60 (0.46,0.79)	0.33 (0.24,0.45)	657,132	287	0.60 (0.48,0.75)	0.36 (0.28,0.47)
15-18	116,291	126	372,449	154	0.71 (0.55,0.92)	0.41 (0.30,0.56)	656,054	308	0.78 (0.62,0.98)	0.57 (0.44,0.75)
19-22	112,000	119	371,770	147	0.65 (0.49,0.86)	0.42 (0.30,0.57)	654,787	301	0.73 (0.57,0.93)	0.49 (0.38,0.64)
23-26	108,374	112	369,894	182	0.84 (0.63,1.11)	0.47 (0.35,0.65)	651,259	315	0.86 (0.66,1.11)	0.58 (0.44,0.77)
27-30	105,672	105	347,928	175	0.89 (0.68,1.17)	0.62 (0.44,0.87)	595,651	322	0.90 (0.71,1.14)	0.64 (0.49,0.85)
31-34	102,725	105	107,639	112	1.84 (1.35,2.52)	1.20 (0.87,1.65)	187,355	175	1.56 (1.18,2.07)	1.18 (0.88,1.59)
35-38	99,547	77	40,432	63	2.95 (2.06,4.24)	2.24 (1.55,3.24)	90,699	98	2.13 (1.56,2.93)	1.63 (1.19,2.23)
39-42	96,278	77	30,891	42	2.40 (1.57,3.67)	1.75 (1.14,2.67)	73,885	63	2.06 (1.41,2.99)	1.82 (1.23,2.68)
43-46	94,864	63	28,903	28	1.73 (1.05,2.83)	1.28 (0.76,2.14)	69,664	49	1.79 (1.23,2.62)	1.42 (0.95,2.13)
47-50	93,590	21	17,507	7	2.41 (0.98,5.93)	2.02 (0.85,4.79)	18,487	14	1.86 (0.76,4.59)	1.51 (0.61,3.77)

Supplementary Table 11: Counts and hazard ratios (HR) for Any SARS-CoV-2 test the 18-64 years and clinically vulnerable subgroup

weeks since second dose	Unvaccinated		BNT162b2				ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR	n	events	unadjusted HR	adjusted HR
3-6	152,572	20,384	373,863	48,503	2.23 (2.19,2.27)	2.04 (2.00,2.09)	658,742	92,666	2.49 (2.45,2.53)	2.23 (2.19,2.27)
7-10	135,653	20,580	373,254	60,256	2.11 (2.07,2.14)	1.95 (1.91,1.99)	656,404	109,935	2.36 (2.32,2.40)	2.11 (2.07,2.15)
11-14	122,136	19,873	371,308	57,442	2.00 (1.96,2.03)	1.83 (1.79,1.87)	649,866	103,271	2.20 (2.17,2.24)	1.98 (1.95,2.02)
15-18	113,092	17,983	368,396	58,737	1.97 (1.93,2.01)	1.78 (1.74,1.82)	641,039	109,018	2.26 (2.22,2.30)	2.01 (1.97,2.04)
19-22	107,212	16,842	364,595	64,687	2.26 (2.22,2.30)	2.00 (1.96,2.04)	631,421	116,522	2.54 (2.50,2.59)	2.20 (2.16,2.24)
23-26	102,802	15,365	359,415	65,919	2.47 (2.42,2.52)	2.12 (2.07,2.17)	618,121	115,262	2.75 (2.71,2.80)	2.35 (2.30,2.39)
27-30	98,840	16,751	332,892	61,334	2.41 (2.37,2.46)	2.11 (2.07,2.16)	552,272	109,956	2.58 (2.53,2.62)	2.24 (2.20,2.28)
31-34	94,864	17,528	98,028	18,431	1.88 (1.84,1.92)	1.76 (1.71,1.80)	161,931	30,779	2.02 (1.98,2.06)	1.90 (1.85,1.94)
35-38	89,509	13,839	34,265	5,341	1.81 (1.75,1.88)	1.65 (1.59,1.71)	72,324	10,073	1.92 (1.86,1.97)	1.74 (1.69,1.79)
39-42	83,545	8,449	24,773	2,142	1.73 (1.65,1.82)	1.53 (1.46,1.62)	56,742	4,697	1.95 (1.88,2.03)	1.75 (1.67,1.82)
43-46	81,578	5,236	23,184	1,603	1.69 (1.59,1.79)	1.49 (1.40,1.58)	53,480	3,185	1.89 (1.80,1.99)	1.69 (1.60,1.78)
47-50	80,619	2,135	14,091	434	1.91 (1.71,2.13)	1.74 (1.55,1.95)	14,070	693	2.04 (1.84,2.26)	1.81 (1.63,2.02)

Supplementary Table 12: Counts and hazard ratios (HR) for COVID-19 hospitalisation the 40-64 years subgroup

weeks since second dose	Unvaccinated		ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR
3-6	315,294	511	1,504,055	63	0.06 (0.04,0.08)	0.05 (0.04,0.07)
7-10	299,026	588	1,502,354	112	0.06 (0.05,0.07)	0.05 (0.04,0.07)
11-14	288,365	602	1,500,534	126	0.05 (0.04,0.07)	0.04 (0.03,0.06)
15-18	280,805	525	1,498,819	175	0.10 (0.09,0.13)	0.09 (0.07,0.11)
19-22	275,310	504	1,496,586	210	0.14 (0.12,0.17)	0.12 (0.10,0.15)
23-26	270,340	553	1,468,761	322	0.18 (0.15,0.21)	0.14 (0.12,0.17)
27-30	265,125	497	1,026,424	273	0.19 (0.16,0.23)	0.18 (0.15,0.23)
31-34	259,210	273	206,864	119	0.74 (0.58,0.95)	0.62 (0.47,0.81)
35-38	255,199	154	148,925	63	1.02 (0.76,1.39)	0.83 (0.61,1.15)
39-42	252,147	70	113,092	42	1.48 (0.96,2.28)	1.12 (0.70,1.80)
43-46	99,624	28	59,332	7	0.76 (0.34,1.69)	0.56 (0.22,1.41)
47-50	3,423	0	70	0		

Supplementary Table 13: Counts and hazard ratios (HR) for COVID-19 death the 40-64 years subgroup

weeks since second dose	Unvaccinated		ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR
3-6	315,329	14	1,504,090	7		
7-10	299,250	21	1,502,452	7		
11-14	288,862	49	1,500,744	7	0.02 (0.01,0.05)	0.01 (0.00,0.04)
15-18	281,512	35	1,499,148	7	0.04 (0.02,0.09)	0.04 (0.01,0.09)
19-22	276,241	35	1,497,076	14	0.06 (0.03,0.13)	0.05 (0.02,0.10)
23-26	271,425	42	1,469,447	21	0.07 (0.04,0.14)	0.06 (0.03,0.14)
27-30	266,399	42	1,027,222	21	0.14 (0.07,0.28)	0.10 (0.05,0.24)
31-34	260,659	35	207,333	7	0.29 (0.12,0.66)	0.26 (0.11,0.64)
35-38	256,767	14	149,324	7		
39-42	253,722	7	113,442	7		
43-46	100,436	7	59,577	0		
47-50	3,465	0	70	0		

Supplementary Table 14: Counts and hazard ratios (HR) for positive SARS-CoV-2 test the 40-64 years subgroup

weeks since second dose	Unvaccinated		ChAdOx1			
	n	events	n	events	unadjusted HR	adjusted HR
3-6	314,615	5,866	1,500,366	9,100	0.91 (0.88,0.95)	0.78 (0.75,0.81)
7-10	296,149	5,985	1,489,642	13,692	1.06 (1.02,1.09)	0.92 (0.89,0.96)
11-14	282,863	5,670	1,474,256	17,731	1.48 (1.43,1.54)	1.27 (1.22,1.32)
15-18	273,161	5,887	1,454,971	20,734	1.83 (1.77,1.89)	1.52 (1.46,1.57)
19-22	265,405	6,860	1,432,242	29,239	2.17 (2.10,2.23)	1.77 (1.71,1.83)
23-26	258,083	9,884	1,377,586	43,428	2.60 (2.54,2.67)	2.18 (2.13,2.24)
27-30	249,795	9,632	934,052	33,656	2.37 (2.30,2.44)	2.07 (2.01,2.14)
31-34	238,924	4,417	160,083	5,320	2.35 (2.24,2.46)	2.03 (1.93,2.13)
35-38	231,945	861	114,191	322	1.95 (1.69,2.25)	1.60 (1.38,1.86)
39-42	228,557	70	89,033	42	1.71 (1.09,2.69)	1.29 (0.80,2.10)
43-46	92,120	28	48,832	7	0.80 (0.36,1.79)	0.59 (0.23,1.47)
47-50	3,255	0	63	0		

Supplementary Table 15: Counts and hazard ratios (HR) for non-COVID-19 death the 40-64 years subgroup

weeks since second dose	Unvaccinated		ChAdOx1		unadjusted HR	adjusted HR
	n	events	n	events		
3-6	315,329	98	1,504,090	91	0.25 (0.18,0.35)	0.27 (0.18,0.41)
7-10	299,250	77	1,502,452	119	0.39 (0.28,0.54)	0.41 (0.28,0.60)
11-14	288,862	84	1,500,744	126	0.41 (0.30,0.56)	0.45 (0.32,0.63)
15-18	281,512	63	1,499,148	161	0.75 (0.53,1.06)	0.82 (0.56,1.20)
19-22	276,241	77	1,497,076	168	0.57 (0.41,0.79)	0.60 (0.42,0.87)
23-26	271,425	70	1,469,447	168	0.56 (0.40,0.78)	0.66 (0.45,0.95)
27-30	266,399	70	1,027,222	140	0.58 (0.40,0.83)	0.65 (0.44,0.97)
31-34	260,659	70	207,333	63	1.33 (0.91,1.95)	1.23 (0.84,1.80)
35-38	256,767	63	149,324	42	1.41 (0.94,2.12)	1.22 (0.80,1.87)
39-42	253,722	42	113,442	35	1.60 (0.99,2.60)	1.52 (0.93,2.48)
43-46	100,436	21	59,577	14	2.13 (0.93,4.91)	2.05 (0.88,4.74)
47-50	3,465	0	70	0		

Supplementary Table 16: Counts and hazard ratios (HR) for Any SARS-CoV-2 test the 40-64 years subgroup

weeks since second dose	Unvaccinated		ChAdOx1		unadjusted HR	adjusted HR
	n	events	n	events		
3-6	314,615	34,706	1,500,366	246,358	3.81 (3.76,3.86)	2.83 (2.79,2.87)
7-10	296,149	34,566	1,489,642	254,555	3.53 (3.48,3.57)	2.67 (2.64,2.71)
11-14	282,863	32,788	1,474,256	255,353	3.75 (3.70,3.80)	2.86 (2.82,2.90)
15-18	273,161	30,786	1,454,971	279,734	4.15 (4.10,4.21)	3.15 (3.11,3.19)
19-22	265,405	31,465	1,432,242	289,226	4.28 (4.23,4.34)	3.26 (3.21,3.30)
23-26	258,083	33,460	1,377,586	296,072	4.42 (4.37,4.48)	3.40 (3.35,3.44)
27-30	249,795	30,898	934,052	211,099	3.73 (3.68,3.79)	2.89 (2.84,2.93)
31-34	238,924	21,350	160,083	19,117	2.68 (2.62,2.74)	2.21 (2.16,2.26)
35-38	231,945	13,125	114,191	7,343	2.31 (2.24,2.39)	1.90 (1.83,1.96)
39-42	228,557	7,266	89,033	4,340	2.49 (2.39,2.61)	2.05 (1.95,2.14)
43-46	92,120	2,541	48,832	1,407	2.84 (2.65,3.06)	2.28 (2.11,2.46)
47-50	3,255	28	63	7		

Supplementary Table 17: Counts and hazard ratios (HR) for COVID-19 hospitalisation the 18-39 years subgroup

weeks since second dose	Unvaccinated		BNT162b2		unadjusted HR	adjusted HR
	n	events	n	events		
3-6	685,622	763	706,454	21	0.04 (0.02,0.06)	0.04 (0.03,0.07)
7-10	653,359	560	701,974	28	0.09 (0.06,0.14)	0.10 (0.07,0.15)
11-14	630,420	574	698,698	42	0.11 (0.08,0.15)	0.10 (0.07,0.15)
15-18	613,081	665	695,541	70	0.18 (0.14,0.23)	0.17 (0.13,0.23)
19-22	595,175	791	584,339	126	0.28 (0.23,0.34)	0.30 (0.24,0.37)
23-26	574,707	630	305,249	84	0.50 (0.40,0.64)	0.49 (0.38,0.63)
27-30	557,340	392	219,170	56	0.63 (0.46,0.85)	0.56 (0.41,0.77)
31-34	548,149	224	178,864	42	0.89 (0.63,1.26)	0.69 (0.48,0.99)
35-38	350,091	56	52,241	14	1.97 (0.96,4.05)	1.48 (0.69,3.17)

Supplementary Table 18: Counts and hazard ratios (HR) for positive SARS-CoV-2 test the 18-39 years subgroup

weeks since second dose	Unvaccinated		BNT162b2				
	n	events	n	events	unadjusted HR	adjusted HR	
3-6	678,657	16,450	701,554	2,744	0.31 (0.30,0.32)	0.25 (0.24,0.26)	
7-10	637,630	14,203	694,400	4,151	0.52 (0.50,0.54)	0.41 (0.39,0.42)	
11-14	609,763	16,688	687,043	7,420	0.75 (0.73,0.78)	0.58 (0.56,0.60)	
15-18	586,173	29,519	676,578	27,195	1.71 (1.68,1.74)	1.36 (1.34,1.39)	
19-22	561,239	35,399	543,718	42,980	2.32 (2.29,2.36)	1.88 (1.85,1.91)	
23-26	523,810	18,200	245,630	12,880	2.52 (2.46,2.58)	1.97 (1.91,2.02)	
27-30	494,970	3,325	164,507	707	2.38 (2.18,2.59)	1.77 (1.62,1.94)	
31-34	484,484	196	134,981	42	1.11 (0.77,1.60)	0.84 (0.57,1.23)	
35-38	310,051	56	38,731	14	2.54 (1.23,5.23)	1.83 (0.85,3.94)	

Supplementary Table 19: Counts and hazard ratios (HR) for non-COVID-19 death the 18-39 years subgroup

weeks since second dose	Unvaccinated		BNT162b2				
	n	events	n	events	unadjusted HR	adjusted HR	
3-6	685,895	28	706,468	7	0.66 (0.27,1.59)	0.64 (0.23,1.76)	
7-10	654,024	28	702,009	7	0.18 (0.05,0.64)	0.16 (0.04,0.59)	
11-14	631,344	21	698,761	7	0.57 (0.21,1.53)	0.67 (0.27,1.68)	
15-18	614,145	21	695,639	14	0.65 (0.29,1.45)	0.64 (0.27,1.53)	
19-22	596,470	21	584,493	7	0.36 (0.09,1.48)	0.34 (0.08,1.47)	
23-26	576,205	21	305,452	7	0.41 (0.10,1.71)	0.34 (0.07,1.60)	
27-30	559,132	14	219,408	7			
31-34	550,060	7	179,095	7			
35-38	351,512	7	52,325	0			

Supplementary Table 20: Counts and hazard ratios (HR) for Any SARS-CoV-2 test the 18-39 years subgroup

weeks since second dose	Unvaccinated		BNT162b2				
	n	events	n	events	unadjusted HR	adjusted HR	
3-6	678,657	101,213	701,554	119,784	2.35 (2.32,2.37)	1.82 (1.80,1.84)	
7-10	637,630	86,037	694,400	120,169	2.71 (2.69,2.74)	2.09 (2.07,2.11)	
11-14	609,763	81,767	687,043	117,593	2.81 (2.78,2.84)	2.13 (2.11,2.15)	
15-18	586,173	100,380	676,578	152,446	2.76 (2.73,2.78)	2.10 (2.08,2.12)	
19-22	561,239	100,191	543,718	145,754	3.02 (2.99,3.04)	2.30 (2.27,2.32)	
23-26	523,810	63,567	245,630	41,895	2.83 (2.79,2.87)	2.16 (2.12,2.19)	
27-30	494,970	34,517	164,507	12,439	2.43 (2.38,2.48)	1.88 (1.84,1.93)	
31-34	484,484	18,284	134,981	6,174	2.39 (2.32,2.47)	1.84 (1.78,1.90)	
35-38	310,051	5,299	38,731	1,141	2.68 (2.51,2.87)	1.92 (1.79,2.06)	